Xinguang Pharmaceutical released its 2026 interim report on August 25, 2026. The company's total operating revenue was 143 million yuan, net profit attributable to the parent company was 39.7121 million yuan, and net cash inflow from operating activities was 57.7783 million yuan. The company's latest asset-liability ratio was 6.05%, gross margin was 46.06%, ROE was 4.79%, and diluted earnings per share was 0.25 yuan. The company's latest total asset turnover was 0.16 times, and inventory turnover was 2.13 times. The number of shareholders was 13,600, and the top ten shareholders held 88.8191 million shares, accounting for 55.51% of the total share capital.
Zhejiang Xinguang Pharmaceutical Co LtdCompany released interim report with net profit of 39.7 million yuan, indicating financial performance.
